Skip to main content
Equibles
VANI logo

VANI · Vivani Medical, Inc.

Track VANI — free

Use VANI with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about VANI

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.40 +0.06 (+4.48%) At close · Aug 14
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions and events raise substantial doubt about our ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. ... Because these plans are not fully within our control and their successful execution cannot be considered certain, management has concluded that its plans do not alleviate the substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$118.14M
Shares
90.20M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.40 Open$1.34 Day$1.34–1.42 52W close$0.94–1.87 Avg vol 30d721K Short int498K · 0.6% float · 2.2d Short vol67% Last earningsMar 13, 2025 DataAug 2022–Aug 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Aug 19, 2022; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +8%
above
Price vs 50-day avg +8%
above
RSI (14) 55
neutral
MACD trend Positive
52-week position 50%
mid-range
Momentum
relative strength
Very Strong
1-month return +6%
trailing
6-month return +12%
trailing
YTD return +14%
this year
Relative strength −2%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-14% holders QoQ · +7 funds added
Insider flow Accumulating
Net +$3.0M over 90 days · 0% sells
Short interest Rising
0.55% of float · ▲ +40.6% MoM · 2.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
38 holders — mid 3-yr range
Squeeze score 47
elevated · 0–100
Fundamentals
Weak
Revenue growth −55%
Y/Y
Gross margin 3%
contracting
EPS growth 0%
Y/Y
Free cash flow $-25.5M
Balance sheet $14.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 73%
annualized · 1-yr
Max drawdown −50%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+8% Bullish
Price vs 50-day avg
+8% Bullish
RSI (14)
55 Neutral
MACD trend
Positive Bullish
52-week position
50% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-14% holders QoQ · +7 funds added
Insider flow Accumulating
Net +$3.0M over 90 days · 0% sells
Short interest Rising
0.55% of float · ▲ +40.6% MoM · 2.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
38 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 50% Range high $2
vs 200-day avg +8% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VANI
Vivani Medical, Inc.
this stock
$118.14M +13.8% -55.1% — 0.6%
ONC
BeOne Medicines Ltd.
 $530.72B +14.4% +22179.2% 816.0 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.25B +11.6% +46.2% 30.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.16B +4.1% +20.8% 19.8 3.3%
ARGX
Argenx SE
 $52.69B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
38
% held
5.6%
Net QoQ
-600.3K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
13
View
Short & Settlement
Short Interest Rising
Shares short
498.2K
Days to cover
2.2d
Change
+143.8K sh
View
Short Volume
Short vol %
67%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
20
Value
$25
As of
Jul 6, 2026
View
Off-Exchange
Off-exchange %
58.0%
Week of
Jul 6, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$3.0M
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$4.0M
Net income (FY)
$-26.6M
EPS diluted
$-0.43
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
14
View
Proposed Sales
Value
$187.7K
Shares
50.2K
Filed
Mar 5, 2024
View
Exempt Offerings
Offering
$27.9M
Filed
Apr 7, 2021
View
Earnings & Events
Earnings Calls
Last call
Jul 15, 2026
View

Performance

Raw-price comparisons begin at the captured split on Aug 19, 2022; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
VANI -0.7% +6.1% +12.0% +9.4% +13.8%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -1.1% +1.6% -1.8% +5.5% 0.0%
Key facts CIK 1266806 CUSIP 92854B109 13F (30d) 37 filings 37 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)